A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

NCT05084963 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Esophagitis

Interventions

DRUG: IRL201104
DRUG: Placebo

Sponsor

Revolo Biotherapeutics